We found no evidence that the level of melatonin is strongly associated with the risk for breast cancer.

The growth of all ERalpha-positive breast cancer cell lines can be inhibited by melatonin (10(-9)M).

Melatonin acts as a calmodulin antagonist inducing conformational changes in the Eralpha-calmodulin (CaM) complex, thus impairing the binding of E(2).

Studies for an association between Mlt suppression, night work as a surrogate, and breast cancer risk.

Independent information about nocturnal light exposure of each case patient and control subject is essential for assessing melatonin-modulated cancer risk.

Night shifts workers seem to experience changes in hormone levels (6-sulfatoxymelatonin) that may be associated with the increased cancer risk observed.

Melatonin acts as a calmodulin antagonist inducing conformational changes in the Eralpha-calmodulin (CaM) complex, thus impairing the binding of E(2).

Studies for an association between Mlt suppression, night work as a surrogate, and breast cancer risk.

Constant light suppressed MLT, increased cancer cell growth rates, and increased linoleic acid (LA) uptake into cancer cells.

No abstract available.